Antifungals Therapeutic Drug Monitoring: Introduction, Clinical Significance, and Keynotes

Introduction of Antifungal Therapeutic Drug Monitoring

• Antifungal drugs require precise dosing to ensure safe patient outcomes.
• Moreover, clinicians track serum levels to avoid toxicity and resistance.
• Therefore, monitoring helps maintain drug concentrations within the therapeutic range.
• In addition, individual metabolism affects how patients process antifungals.
• Consequently, tailored dosing prevents underexposure and treatment failure.

Clinical Significance

• Physicians measure trough levels before the next dose.
• Furthermore, adjusted doses improve efficacy in severe fungal infections.
• However, patient factors such as age and organ function alter clearance.
• In contrast, standard dosing may harm those with impaired clearance.
• As a result, drug monitoring guides dose adjustments in real time.
• Moreover, it reduces adverse events like hepatotoxicity and nephrotoxicity.

Keynotes on Antifungal Therapeutic Drug Monitoring

• Implement monitoring for azoles and echinocandins when available.
• Additionally, validate assays in each laboratory setting.
• Therefore, levels should be correlated with clinical response and side effects.
• Therapeutic drug monitoring (TDM) for antifungal medications is crucial for optimizing treatment outcomes, particularly with drugs exhibiting a narrow therapeutic index or unpredictable pharmacokinetics. It helps to minimize toxicity associated with high drug levels and prevent treatment failure due to low levels. TDM is generally recommended for certain azole antifungals, like itraconazole, voriconazole, posaconazole, and flucytosine.
• TDM involves measuring drug concentrations in patient samples, often using techniques like high-performance liquid chromatography (HPLC) or liquid chromatography-mass spectrometry.
• TDM can help prevent treatment failure, reduce drug-related toxicity, and potentially prevent the development of drug resistance.
• TDM is especially important in patients with invasive fungal infections, those with impaired liver or kidney function, and those receiving prolonged antifungal prophylaxis.
• TDM for some antifungals, like fluconazole and echinocandins, is not routinely recommended due to limited evidence of benefit.
• Higher concentrations of some antifungals can lead to adverse events like nausea, vomiting, and liver enzyme elevation.
• In practice, multidisciplinary teams optimize antifungal therapy.
• Finally, ongoing research refines concentration–effect relationships.

Further Readings

• https://pmc.ncbi.nlm.nih.gov/articles/PMC3977608/
• https://www.sciencedirect.com/science/article/pii/S1198743X20303359
• https://academic.oup.com/ofid/article/10/9/ofad468/7270441
• https://academic.oup.com/ofid/article/10/9/ofad468/7270441
• https://www.sciencedirect.com/science/article/abs/pii/S1341321X24002769
• https://www.sciencedirect.com/science/article/pii/S1341321X24002769